Beyond Trastuzumab: Overcoming Resistance to Targeted HER-2 Therapy in Breast Cancer

被引:48
|
作者
Bedard, Philippe L. [1 ]
de Azambuja, Evandro [1 ]
Cardoso, Fatima [1 ]
机构
[1] Inst Jules Bordet, B-1000 Brussels, Belgium
关键词
Breast neoplasms; erbB-2; receptor; monoclonal antibodies; protein-tyrosine kinases; ACTIVATED PROTEIN-KINASE; PHASE-II TRIAL; C-MYC AMPLIFICATION; TYROSINE KINASE; MONOCLONAL-ANTIBODY; ADJUVANT CHEMOTHERAPY; PROGNOSTIC-SIGNIFICANCE; ANTI-ERBB2; ANTIBODIES; EXTRACELLULAR DOMAIN; CELL-PROLIFERATION;
D O I
10.2174/156800909787581024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Overexpression of the human epidermal growth factor receptor 2 (HER-2) represents a biological subclass of breast cancer with distinct molecular alterations, clinical behavior, and response to systemic therapy. Trastuzumab is a monoclonal antibody directed against HER-2 which has revolutionized the management of both early and advanced breast cancer. It may exert its anti-cancer effects through inhibition of intracellular signaling, upregulation of p27, impaired angiogenesis, induction of immune-mediated destruction, and blockade of cleavage of the extracellular domain of HER-2. In spite of its robust clinical activity, most women with metastatic HER-2 overexpressing breast cancer eventually progress on trastuzumab therapy. Possible mechanisms of resistance include: altered receptor antibody interaction, PTEN loss and enhanced Akt signaling, p27 loss, signaling through other receptors. Preclinical experiments, clinical experience with the use of trastuzumab beyond progression, and a recent phase III clinical trial with Lapatinib, a dual EGFR/HER-2 tyrosine kinase inhibitor, demonstrate that the HER-2 signaling axis remains an important therapeutic target even after progression on trastuzumab. A variety of novel strategies are currently in development to exploit this pathway following the onset of resistance, such as receptor antibodies, sheddase inhibitors, signal transduction inhibitors, heat shock protein inhibitors, proteasome inhibitors, anti-angiogenic agents, and immune-stimulatory therapies, either as single agents or in combination with trastuzumab. Rational clinical trial design, with attention to appropriate patient selection and prospective collection of biological material, is needed to ensure that the new generation of anti-HER-2 targeted therapies realizes its promise in the treatment of trastuzumab-resistant disease.
引用
收藏
页码:148 / 162
页数:15
相关论文
共 50 条
  • [21] Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer
    Sharial, M. S. N. Mohd
    Crown, J.
    Hennessy, B. T.
    ANNALS OF ONCOLOGY, 2012, 23 (12) : 3007 - 3016
  • [22] HER-2 as a Target for Breast Cancer Therapy
    Ignatiadis, Michail
    Desmedt, Christine
    Sotiriou, Christos
    de Azambuja, Evandro
    Piccart, Martine
    CLINICAL CANCER RESEARCH, 2009, 15 (06) : 1848 - 1852
  • [23] Evaluation of Cardiotoxicity in HER-2 Positive Breast Cancer Patients Treated With Radiation Therapy and Trastuzumab
    Bachir, B.
    Anouti, S.
    Jaoude, J. Abi
    Kayali, M.
    Tfayli, A.
    De Azambuja, E.
    Poortmans, P.
    Zeidan, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : S7 - S7
  • [24] Targeting HER2 in breast cancer: beyond trastuzumab
    EP Winer
    Breast Cancer Research, 13
  • [25] Targeting HER2 in breast cancer: beyond trastuzumab
    Winer, F. P.
    BREAST CANCER RESEARCH, 2011, 13
  • [26] HER2-Positive Breast Cancer: Beyond Trastuzumab
    Murphy, Conleth G.
    Fornier, Monica
    ONCOLOGY-NEW YORK, 2010, 24 (05): : 410 - 415
  • [27] HER-2 positive breast cancer and trastuzumab: lessons learnt by heart
    Outhoff, k
    SOUTHERN AFRICAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2009, 1 (02) : 52 - 57
  • [28] HER2 targeted therapy in breast cancer...beyond Herceptin
    Sumanta Kumar Pal
    Mark Pegram
    Reviews in Endocrine and Metabolic Disorders, 2007, 8 : 269 - 277
  • [29] HER2 targeted therapy in breast cancer...beyond Herceptin
    Pal, Sumanta Kumar
    Pegram, Mark
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2007, 8 (03): : 269 - 277
  • [30] HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
    Gajria, Devika
    Chandarlapaty, Sarat
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (02) : 263 - 275